Table 1. Open in new tab Summaries of...

Table 1.

Open in new tab

Summaries of studies on monospecific anti-DFS70 in systemic rheumatic diseases.

In a Danish study, the prevalence of anti-DFS70 (tested by CLIA) was 2% (5/249) in blood donors and 2.3% in SLE patients (3/131) (34). The prevalence in Danish blood donors was comparable to the presence of anti-DFS70 in other European countries [1.2% in Italy, 1.7% in Spain/Belgium, 2% in the UK, and 4.2% in Germany (28)]. Monospecific anti-DFS70 was found in none of the Danish SLE patients.
An Italian study (35) reported 7 cases with anti-DFS70 antibodies (tested by CLIA) out of 333 AARD cases (2.1%) (none was monospecific), 9 cases with anti-DFS70 antibodies out of 384 non-AARD cases (2.3%) (of which 2 were monospecific), and 3 cases with anti-DFS70 antibodies out of 51 UCTD cases (5.8%) (of which all 3 were monospecific). The authors concluded that monospecific anti-DFS70 might be helpful to discriminate AARD from non-AARD (35).
In a Japanese study, the overall prevalence of anti-DFS70 antibodies in healthy individuals was comparable to the prevalence in individuals with AARD, but the prevalence of monospecific anti-DFS70 (tested by ELISA, MBL) was higher in healthy individuals than in individuals with AARD (14.8% in 250 healthy individuals vs 4.4% in 204 patients with AARD) (19). Note the high prevalence of anti-DFS70 antibodies in this study, which may point toward geographical differences in anti-DFS70 prevalence.
A Canadian study evaluated the clinical utility of anti-DFS70 (tested by CLIA) in a central triage system. Of 643 ANA-positive patients/sera referred through a central triage system, 15.1% were anti-DFS70 positive (by CLIA) and 91.2% of these did not have an AARD (36). The likelihood ratio (LR)+ for non-AARD was 5.4 for anti-DFS70 and 10.9 for monospecific anti-DFS70 10.9 (36).
A study from Turkey investigated anti-DFS70 (Euroimmun blot) in 3432 serum samples tested for ANA (37). Monospecific anti-DFS70 was found in 7 out of 390 (1.8%) systemic rheumatic disease (AARD, RA) cases and in 143 out of 3042 (4.7%) cases without systemic rheumatic disease. The LR to exclude systemic rheumatic disease was 1.2 for anti-DFS70 and 2.6 for monospecific anti-DFS70.
In a German study, Mockenhaupt et al. (38) reported 21 anti-DFS70 positive (line immunoassay, Euroimmun) patients out of 182 AARD patients. One of these patients (IIM) had monospecific anti-DFS70, the others had disease-specific/associated antibodies (e.g., anti-dsDNA, anti-Sm in SLE, anti-SSA in SS, anti-Scl70 in SSc). These authors concluded that autoantibodies to DFS70 seem to be prevalent in CTD patients and are thus not a good exclusion criterion. As the occurrence of monospecific anti-DFS70 was rare, the authors concluded that monospecific anti-DFS70 can be helpful in ambiguous situations.
Muro et al. (39) (Japanese study) reported monospecific anti-DFS70 (tested by immunoblotting against purified recombinant DFS70) in 1/7 anti-DFS70 positive patients with Sjögren syndrome (out of 71 SS patients) and in 2/4 anti-DFS70-positive patients with dermatomyositis (out of 80 DM/PM patients).
Choi et al. (15) reported monospecific anti-DSF70 antibodies (tested by CLIA) in 13 of 1137 SLE patients (international cohort) (1.1%). This large study confidently documented that monospecific anti-DFS70 exists in SLE, albeit at a low frequency.
In a Belgian study, Bonroy et al. (20) described 25 ANA-positive monospecific anti-DFS70 cases (detected by CLIA) (21 from a secondary care center and 4 from a tertiary care center). In 2 of them (both cases were from a tertiary care center) AARD was present (1 SLE and 1 SSc).

In a Danish study, the prevalence of anti-DFS70 (tested by CLIA) was 2% (5/249) in blood donors and 2.3% in SLE patients (3/131) (34). The prevalence in Danish blood donors was comparable to the presence of anti-DFS70 in other European countries [1.2% in Italy, 1.7% in Spain/Belgium, 2% in the UK, and 4.2% in Germany (28)]. Monospecific anti-DFS70 was found in none of the Danish SLE patients.
An Italian study (35) reported 7 cases with anti-DFS70 antibodies (tested by CLIA) out of 333 AARD cases (2.1%) (none was monospecific), 9 cases with anti-DFS70 antibodies out of 384 non-AARD cases (2.3%) (of which 2 were monospecific), and 3 cases with anti-DFS70 antibodies out of 51 UCTD cases (5.8%) (of which all 3 were monospecific). The authors concluded that monospecific anti-DFS70 might be helpful to discriminate AARD from non-AARD (35).
In a Japanese study, the overall prevalence of anti-DFS70 antibodies in healthy individuals was comparable to the prevalence in individuals with AARD, but the prevalence of monospecific anti-DFS70 (tested by ELISA, MBL) was higher in healthy individuals than in individuals with AARD (14.8% in 250 healthy individuals vs 4.4% in 204 patients with AARD) (19). Note the high prevalence of anti-DFS70 antibodies in this study, which may point toward geographical differences in anti-DFS70 prevalence.
A Canadian study evaluated the clinical utility of anti-DFS70 (tested by CLIA) in a central triage system. Of 643 ANA-positive patients/sera referred through a central triage system, 15.1% were anti-DFS70 positive (by CLIA) and 91.2% of these did not have an AARD (36). The likelihood ratio (LR)+ for non-AARD was 5.4 for anti-DFS70 and 10.9 for monospecific anti-DFS70 10.9 (36).
A study from Turkey investigated anti-DFS70 (Euroimmun blot) in 3432 serum samples tested for ANA (37). Monospecific anti-DFS70 was found in 7 out of 390 (1.8%) systemic rheumatic disease (AARD, RA) cases and in 143 out of 3042 (4.7%) cases without systemic rheumatic disease. The LR to exclude systemic rheumatic disease was 1.2 for anti-DFS70 and 2.6 for monospecific anti-DFS70.
In a German study, Mockenhaupt et al. (38) reported 21 anti-DFS70 positive (line immunoassay, Euroimmun) patients out of 182 AARD patients. One of these patients (IIM) had monospecific anti-DFS70, the others had disease-specific/associated antibodies (e.g., anti-dsDNA, anti-Sm in SLE, anti-SSA in SS, anti-Scl70 in SSc). These authors concluded that autoantibodies to DFS70 seem to be prevalent in CTD patients and are thus not a good exclusion criterion. As the occurrence of monospecific anti-DFS70 was rare, the authors concluded that monospecific anti-DFS70 can be helpful in ambiguous situations.
Muro et al. (39) (Japanese study) reported monospecific anti-DFS70 (tested by immunoblotting against purified recombinant DFS70) in 1/7 anti-DFS70 positive patients with Sjögren syndrome (out of 71 SS patients) and in 2/4 anti-DFS70-positive patients with dermatomyositis (out of 80 DM/PM patients).
Choi et al. (15) reported monospecific anti-DSF70 antibodies (tested by CLIA) in 13 of 1137 SLE patients (international cohort) (1.1%). This large study confidently documented that monospecific anti-DFS70 exists in SLE, albeit at a low frequency.
In a Belgian study, Bonroy et al. (20) described 25 ANA-positive monospecific anti-DFS70 cases (detected by CLIA) (21 from a secondary care center and 4 from a tertiary care center). In 2 of them (both cases were from a tertiary care center) AARD was present (1 SLE and 1 SSc).

This Feature Is Available To Subscribers Only